Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs
SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ — Lunit (KRX:328130), a leader in AI for cancer diagnostics and precision oncology, has announced a partnership with Daiichi Sankyo (TSE: 4568) aimed at accelerating biomarker discovery and enhancing translational research. This collaboration will integrate Lunit’s AI-powered digital pathology products, including the SCOPE IO and SCOPE uIHC, across two oncology pipeline programs.
Daiichi Sankyo plans to implement various Lunit SCOPE solutions to explore novel biomarkers that may enrich clinical trials and support precision patient stratification within select oncology programs. The use of SCOPE uIHC will enable quantitative immunohistochemistry (IHC) analysis, while SCOPE IO will facilitate immune phenotyping and spatial analysis.
“Lunit SCOPE was built to unlock hidden insights from pathology slides—quantifying the tumor microenvironment, predicting molecular profiles, and generating data-rich features to inform trial design,” stated Brandon Suh, CEO of Lunit. “By working with Daiichi Sankyo, we are embedding these capabilities into translational and clinical research, enabling faster biomarker discovery and more precise patient stratification. Ultimately, this means more efficient trials and better outcomes, where each patient has a greater chance of receiving the therapy that works best for them.”
The collaboration will encompass exploratory research projects and analyses across two oncology assets targeting multiple cancer types, with the potential to inform future trial designs, biomarker strategies, and clinical development plans.
Founded in 2013, Lunit is on a mission to conquer cancer through AI, providing clinically validated solutions that span medical imaging, breast health, and biomarker analysis. Its offerings empower earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit’s comprehensive suite includes risk prediction and early detection tools, as well as precision oncology solutions. Its FDA-cleared Lunit INSIGHT suite and breast health solutions are designed to support cancer screening in thousands of medical institutions worldwide. Additionally, the Lunit SCOPE platform is utilized in research partnerships with global pharmaceutical and laboratory leaders for biomarker research and companion diagnostic development.
With over 10,000 sites across more than 65 countries relying on its expertise, Lunit combines deep medical knowledge with continuously evolving datasets to generate measurable impacts for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is at the forefront of the worldwide fight against cancer. More information can be found at lunit.io/en.
As the integration of AI technologies continues to transform cancer research and treatment, this collaboration marks a significant step towards more efficient and effective clinical trials, highlighting the potential for enhanced patient outcomes through precision medicine.
See also
Nvidia Surges 0.70% as Strong H200 Demand from China Boosts AI Outlook
TIL Limited Unveils Three Indigenous Products at EXCON 2025, Enhancing India’s Infrastructure Solutions
Microsoft AI CEO Mustafa Suleyman Calls Elon Musk a ‘Bulldozer’ with ‘Superhuman Capabilities’
AI Bubble Insights: Housing Market Booms in SF Amid Industry Risks and GPU-TPU Shift
CoreWeave Stock Plummets 7.9% Amid Insider Sales, $20M AI Hub Fund Launched
